Microelectrode Arrays Emerge as a Powerful Tool for Detecting Cancer Drug

A review in Frontiers in Electronics argues that preclinical testing tools for cardiotoxicity in cancer drugs need an upgrade, as heart risk can emerge long after treatment ends. The piece frames the field as cardio-oncology and, more specifically, precision cardio-oncology, which aims to predict cardiac danger before a patient receives a first dose. Two major concerns are highlighted: arrhythmias that can lead to sudden cardiac arrest, and contractility dysregulation that can progress toward cardiomyopathy. The current benchmark mentioned is CiPA, launched in 2013 after drugs were withdrawn for fatal arrhythmias. CiPA uses a tiered approach combining in vitro measurements, computer simulations, and clinical evidence, including for chemotherapeutics. The review describes in vitro tools such as patch clamp and impedance measurements, noting accuracy depends on the technologies used.